1
|
Daňhelovská T, Zdražilová L, Štufková H, Vanišová M, Volfová N, Křížová J, Kuda O, Sládková J, Tesařová M. Knock-Out of ACBD3 Leads to Dispersed Golgi Structure, but Unaffected Mitochondrial Functions in HEK293 and HeLa Cells. Int J Mol Sci 2021; 22:ijms22147270. [PMID: 34298889 PMCID: PMC8303370 DOI: 10.3390/ijms22147270] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 06/29/2021] [Accepted: 07/01/2021] [Indexed: 11/30/2022] Open
Abstract
The Acyl-CoA-binding domain-containing protein (ACBD3) plays multiple roles across the cell. Although generally associated with the Golgi apparatus, it operates also in mitochondria. In steroidogenic cells, ACBD3 is an important part of a multiprotein complex transporting cholesterol into mitochondria. Balance in mitochondrial cholesterol is essential for proper mitochondrial protein biosynthesis, among others. We generated ACBD3 knock-out (ACBD3-KO) HEK293 and HeLa cells and characterized the impact of protein absence on mitochondria, Golgi, and lipid profile. In ACBD3-KO cells, cholesterol level and mitochondrial structure and functions are not altered, demonstrating that an alternative pathway of cholesterol transport into mitochondria exists. However, ACBD3-KO cells exhibit enlarged Golgi area with absence of stacks and ribbon-like formation, confirming the importance of ACBD3 in Golgi stacking. The glycosylation of the LAMP2 glycoprotein was not affected by the altered Golgi structure. Moreover, decreased sphingomyelins together with normal ceramides and sphingomyelin synthase activity reveal the importance of ACBD3 in ceramide transport from ER to Golgi.
Collapse
Affiliation(s)
- Tereza Daňhelovská
- Department of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, 128 01 Prague, Czech Republic; (T.D.); (L.Z.); (H.Š.); (M.V.); (N.V.); (J.K.); (J.S.)
| | - Lucie Zdražilová
- Department of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, 128 01 Prague, Czech Republic; (T.D.); (L.Z.); (H.Š.); (M.V.); (N.V.); (J.K.); (J.S.)
| | - Hana Štufková
- Department of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, 128 01 Prague, Czech Republic; (T.D.); (L.Z.); (H.Š.); (M.V.); (N.V.); (J.K.); (J.S.)
| | - Marie Vanišová
- Department of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, 128 01 Prague, Czech Republic; (T.D.); (L.Z.); (H.Š.); (M.V.); (N.V.); (J.K.); (J.S.)
| | - Nikol Volfová
- Department of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, 128 01 Prague, Czech Republic; (T.D.); (L.Z.); (H.Š.); (M.V.); (N.V.); (J.K.); (J.S.)
| | - Jana Křížová
- Department of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, 128 01 Prague, Czech Republic; (T.D.); (L.Z.); (H.Š.); (M.V.); (N.V.); (J.K.); (J.S.)
| | - Ondřej Kuda
- Institute of Physiology, Academy of Sciences of the Czech Republic, 142 00 Prague, Czech Republic;
| | - Jana Sládková
- Department of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, 128 01 Prague, Czech Republic; (T.D.); (L.Z.); (H.Š.); (M.V.); (N.V.); (J.K.); (J.S.)
| | - Markéta Tesařová
- Department of Paediatrics and Inherited Metabolic Disorders, Charles University, First Faculty of Medicine and General University Hospital in Prague, 128 01 Prague, Czech Republic; (T.D.); (L.Z.); (H.Š.); (M.V.); (N.V.); (J.K.); (J.S.)
- Correspondence:
| |
Collapse
|
2
|
Pashikanti S, Afrin F, Meldrum TC, Stegelmeier JL, Pavek A, Habashi YA, Fatema K, Barrott JJ. Quantifying Fluorescently Labeled Ceramide Levels in Human Sarcoma Cell Lines in Response to a Sphingomyelin Synthase Inhibitor. Methods Protoc 2019; 2:mps2030076. [PMID: 31480447 PMCID: PMC6789850 DOI: 10.3390/mps2030076] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 08/12/2019] [Accepted: 08/29/2019] [Indexed: 12/15/2022] Open
Abstract
Sphingolipid metabolism is an important process in sustaining the growth needs of rapidly dividing cancer cells. Enzymes that synthesize sphingolipids have become attractive targets in cancer pharmacology. Ceramide is a precursor for synthesizing sphingolipids such as sphingomyelin, sphingosine-1-phosphate, and glucosylceramide. Sphingomyelin synthase (SMS) is the enzyme that transfers a phosphatidylcholine to ceramide to generate sphingomyelin. To test the inhibition of SMS, scientists assess the buildup of ceramide in the cell, which is cytotoxic. Because ceramide is a small lipid molecule, there are limited tools like antibodies to detect its presence. Alternatively, designated machines for small-molecule separation coupled with mass spectrometry detection can be used; however, these can be cost-prohibitive. We used a commercially available NBD-ceramide to apply to human cancer cell lines in the presence or absence of a known SMS inhibitor, jaspine B. After short incubation times, we were able to collect cell lysates and using solvent extraction methods, run the cellular material on a thin-layer chromatography plate to determine the levels of intact fluorescently labeled ceramide. Brighter fluorescence on the TLC plate correlated to greater SMS inhibition. Small molecules can then be screened quantifiably to determine the biological impact of inhibiting the sphingolipid metabolism pathways involving ceramide.
Collapse
Affiliation(s)
- Srinath Pashikanti
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
| | - Farjana Afrin
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
| | - Trevor C Meldrum
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
| | - John L Stegelmeier
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
| | - Adriene Pavek
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
| | - Yashar A Habashi
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
| | - Kaniz Fatema
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA
| | - Jared J Barrott
- Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, ID 83209, USA.
| |
Collapse
|
3
|
Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, Filleron T, Colacios C, Levade T, Daher A, Meyer N, Andrieu-Abadie N, Ségui B. Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. Front Pharmacol 2019; 10:443. [PMID: 31114500 PMCID: PMC6503817 DOI: 10.3389/fphar.2019.00443] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2018] [Accepted: 04/08/2019] [Indexed: 12/25/2022] Open
Abstract
Sphingolipid (SL) metabolism alterations have been frequently reported in cancer including in melanoma, a bad-prognosis skin cancer. In normal cells, de novo synthesized ceramide is mainly converted to sphingomyelin (SM), the most abundant SL, by sphingomyelin synthase 1 (SMS1) and, albeit to a lesser extent, SMS2, encoded by the SGMS1 and SGMS2 genes, respectively. Alternatively, ceramide can be converted to glucosylceramide (GlcCer) by the GlcCer synthase (GCS), encoded by the UGCG gene. Herein, we provide evidence for the first time that SMS1 is frequently downregulated in various solid cancers, more particularly in melanoma. Accordingly, various human melanoma cells displayed a SL metabolism signature associated with (i) a robust and a low expression of UGCG and SGMS1/2, respectively, (ii) higher in situ enzyme activity of GCS than SMS, and (iii) higher intracellular levels of GlcCer than SM. SMS1 was expressed at low levels in most of the human melanoma biopsies. In addition, several mutations and increased CpG island methylation in the SGMS1 gene were identified that likely affect SMS1 expression. Finally, low SMS1 expression was associated with a worse prognosis in metastatic melanoma patients. Collectively, our study indicates that SMS1 downregulation in melanoma enhances GlcCer synthesis, triggering an imbalance in the SM/GlcCer homeostasis, which likely contributes to melanoma progression. Evaluating SMS1 expression level in tumor samples might serve as a biomarker to predict clinical outcome in advanced melanoma patients.
Collapse
Affiliation(s)
- Fatima Bilal
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France.,Ecole Doctorale de Sciences et Technologies, Université Libanaise, Beirut, Lebanon.,Université Toulouse III - Paul Sabatier, Toulouse, France
| | - Anne Montfort
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France.,Université Toulouse III - Paul Sabatier, Toulouse, France
| | | | - Virginie Garcia
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France
| | - Joëlle Riond
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France
| | - Stéphane Carpentier
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France.,Université Toulouse III - Paul Sabatier, Toulouse, France
| | | | - Céline Colacios
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France.,Université Toulouse III - Paul Sabatier, Toulouse, France
| | - Thierry Levade
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France.,Université Toulouse III - Paul Sabatier, Toulouse, France.,Laboratoire de Biochimie, CHU Purpan, Institut Fédératif de Biologie, Toulouse, France
| | - Ahmad Daher
- Ecole Doctorale de Sciences et Technologies, Université Libanaise, Beirut, Lebanon
| | - Nicolas Meyer
- INSERM UMR 1037, CRCT, Toulouse, France.,Université Toulouse III - Paul Sabatier, Toulouse, France.,Institut Universitaire du Cancer, Toulouse, France
| | - Nathalie Andrieu-Abadie
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France
| | - Bruno Ségui
- INSERM UMR 1037, CRCT, Toulouse, France.,Equipe Labellisée Ligue Contre Le Cancer, Toulouse, France.,Université Toulouse III - Paul Sabatier, Toulouse, France
| |
Collapse
|